Fat cells retain hunger signal after weight loss, potentially driving obesity relapse

by Ansley Kelm, University Hospitals Cleveland Medical Center

edited by Sadie Harley, reviewed by Robert Egan

Sadie Harley

Scientific Editor

Meet our editorial team
Behind our editorial process

Robert Egan

Senior Editor

Meet our editorial team
Behind our editorial process Editors' notes

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

trusted source

proofread

The GIST Add as preferred source

Two enduring biological mysteries have remained unsolved for decades: why almost everyone who loses weight gains it back, no matter how they lost it, and why obesity passes from mother to child at rates that diet and environment cannot explain. Now, scientists from Harrington Discovery Institute at University Hospitals and Case Western Reserve University have identified why.

In a study published in Cell Reports, researchers found that obesity creates a lasting biological change in fat cells that keeps the hunger hormone asprosin elevated ("obesity memory") even after weight loss. The findings may help explain why many people regain weight after dieting or discontinuing GLP-1 medications and why obesity risk can persist across generations.

"Imagine having an appetite-stimulating signal stuck in the 'on' position day after day, despite losing weight," explained Atul Chopra, M.D., Ph.D., senior author of the study, investigator and associate director of the Harrington Rare Disease Program at Harrington Discovery Institute at UH, and associate professor of medicine, genetics and genomics at Case Western Reserve University School of Medicine.

"Our findings suggest one reason weight regain can be so difficult to prevent after treatment ends. This same signal can also cross the placenta from mother to baby. The result is a child born with a programmed susceptibility to obesity. This may also explain why obesity became an epidemic and why the cycle has continued for generations."

Blocking asprosin changed the outcome

The researchers also found that blocking the asprosin pathway in mice, from the gene that produces it to the receptor in the brain that responds to it, prevented both weight regain after dieting and inherited obesity risk. The finding points to new therapeutic strategies that could address the relapse problem drug companies are actively trying to solve.

"These patterns have been observed for decades, but nobody knew the exact molecular mechanism that makes obesity so persistent or how it transmits across generations," Chopra added. "We wanted to find the biological basis for that persistence."

A switch that stayed on

The researchers initiated the study in search of what turns up the hunger hormone asprosin in obesity. They found that an inflammatory signal, called TGF-β1, does this. The biggest surprise was that a brief exposure to this signal created a lasting change that persisted for weeks after the signal was gone.

"It was like flipping a light switch that stays on even after you remove your finger," Chopra said. "Even after mice lost all the excess weight and TGF-β1 returned to normal, this switch in their fat cells remained flipped, keeping asprosin and appetite elevated.

"This gives us a molecular explanation for why GLP-1 drugs, which suppress appetite while you take them, cannot fix the underlying biological memory that drives hunger back up once treatment ends. This same signal crosses the placenta and programs a baby's fat cells before birth."

Chopra said the key message for clinicians is that obesity relapse is not a failure of willpower or discipline. It is driven by a durable biological memory written into fat tissue that sustains hunger long after the pounds come off.

"We need to treat obesity as a condition that leaves lasting biological scars, not just a temporary state of excess weight," he said.

Evidence beyond one lab

This explains why patients on GLP-1 medications regain weight when they discontinue the drugs. The medication suppresses appetite temporarily but does not erase the epigenetic memory in fat cells.

Pharmaceutical companies are actively seeking ways to help people maintain weight loss after treatment. The new findings identify a potential complementary target: a pathway that may sustain the biological drive toward regain after weight reduction.

The study was designed to test its central observation beyond a single laboratory. A separate laboratory led by Seth J. Field, M.D., Ph.D., reproduced the key persistence finding. Field is director of physician-scientist programs and chief scientific officer at the Harrington Discovery Institute at UH and a professor at Case Western Reserve School of Medicine.

Analyses of publicly available mouse and human datasets also yielded supporting evidence. While further human research is needed, the convergence across laboratories and datasets strengthens the case that the mechanism warrants serious investigation.

Turning to human trials

The critical next step in this research is translating the findings into humans. The researchers plan to confirm that the same epigenetic memory operates in human fat tissue after weight loss and test whether therapies that block asprosin or reset these epigenetic marks can prevent weight regain in people.

"Given the need for durable obesity treatments, we are interested in whether asprosin-blocking therapies could be used alongside or after GLP-1 treatment to prevent rebound," Chopra concluded.

Publication details

Brian C. Kim et al, Adipose TGFβ-asprosin memory promotes obesity relapse and offspring obesity susceptibility, Cell Reports (2026). DOI: 10.1016/j.celrep.2026.117809

Journal information: Cell Reports

Key medical concepts

Obesitytransforming growth factor beta 1

Clinical categories

EndocrinologyWeight management Provided by University Hospitals Cleveland Medical Center Who's behind this story?

Sadie Harley

BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

Citation: Fat cells retain hunger signal after weight loss, potentially driving obesity relapse (2026, September 11) retrieved 11 September 2026 from https://medicalxpress.com/news/2026-09-fat-cells-retain-hunger-weight.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.